Evaluation of the Impact of Intensive Short-Term Drug Therapy in Patients With Type 2 Diabetes Mellitus

NCT04027023 on ClinicalTrials.gov · last registry update 2021-04-01

A small phase 4 — 9 participants, against a typical 75. Its estimated completion date, 30 April 2021, has passed with no update to the record. Primary outcome, as filed: impact of a temporary personalized poly-pharmaceutical treatment on the disease stage in patients with type 2 diabetes. A lapsed estimate is not a result and not a failure — sponsors are slow to refile — but ClinicalTrials.gov marks it nowhere on the record, so it is noted here. liraglutide is already approved in the US for type 2 diabetes, so this is asking a further question rather than establishing the drug works at all.

Status: UNKNOWN
Phase: P4
Drug: liraglutide
Saxenda, Victoza, Xultophy
Sponsor: Sciema UG
Sponsor type: Other
Enrollment: 9
Started: 2019-10-30
Primary completion: 2021-04-30 estimated

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

impact of a temporary personalized poly-pharmaceutical treatment on the disease stage in patients with type 2 diabetes

Conditions studied

Diabetes Mellitus, Type 2

Every field above is taken directly from the registry record. See all detected changes across the class, or the liraglutide page for this molecule’s full trial and approval history.